Firma 4SC, Autor bei PR-Web

4SC AG: Poster presentation at the ESMO Virtual Congress 2020

Posted on 17. September 2020 by Firma 4SC Posted in General Tagged 4sc, avelumab, axitinib, bavencio, cancer, domatinostat, hepatitis, hypothyroidism, merck, merklin, patients, pediatric, pneumonitis, statements, with

4SC AG (4SC, FSE Prime Standard: VSC) today announced that a Trial in Progress poster entitled: 1153TiP – A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab (BAVENCIO®) in patients with […]

4SC AG: 4SC expands avelumab supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer

Posted on 15. September 2020 by Firma 4SC Posted in Research / Development Tagged 4sc, avelumab, axitinib, bavencio, cancer, domatinostat, hepatitis, hypertension, hypothyroidism, merck, patients, pediatric, pneumonitis, statements, with

Combination of domatinostat (HDAC inhibitor) and checkpoint inhibitor avelumab (anti-PD-L1 antibody) to be investigated in a second clinical study in Merkel cell carcinoma (MERKLIN 1 study) 4SC AG (4SC, FSE Prime Standard: VSC) today announced that it has entered into […]

4SC and Maruho Discontinue Collaboration for Development of 4SC’s Kv1.3 Inhibitors

Posted on 11. September 2020 by Firma 4SC Posted in Research / Development Tagged 4sc, 4sc's, any, cell, cells, diseases, financial, immune, kv13, maruho, new, press, risks, statements, voltage

Maruho and 4SC agree to terminate their development agreement related to 4SC’s Kv1.3 inhibitors. 4SC to reacquire all rights to the development program. – 4SC AG (4SC, FSE Prime Standard: VSC) today announced that 4SC and Maruho decided to discontinue […]

4SC AG: 4SC provides Q2 2020 and H1 2020 update

Posted on 11. August 2020 by Firma 4SC Posted in General Tagged 4sc, avelumab, bavencio, cell, clinical, domatinostat, forecast, merklin, micro, patients, resmain, resminostat, satellite, statements, with

4SC AG (4SC, FSE Prime Standard: VSC) today published its Half-Year Report 2020, presenting all material developments up to 30 June 2020 and the Company’s current outlook. The full communication is available for download on 4SC’s website. Jason Loveridge, Ph.D., […]